CCNE1 Amplification as a Therapeutic Target

ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib

(2022) Zena Wilson et al.   CANCER RESEARCH

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition

(2022) David Gallo et al.   NATURE

IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.

(2022) George Au-Yeung et al.   JOURNAL OF CLINICAL ONCOLOGY

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

(2021) Stephanie Lheureux et al.   LANCET

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma

(2021) Joyce F. Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

(2021) Naoko Takebe et al.   CLINICAL CANCER RESEARCH

Quantifying CDK inhibitor selectivity in live cells

(2020) Carrow I. Wells et al.   Nature Communications

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

(2020) Panagiotis A Konstantinopoulos et al.   LANCET ONCOLOGY

Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma

(2020) Angela MY Chan et al.   Journal of Pathology Clinical Research

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

(2020) Andrea Ghelli Luserna di Rorà et al.   Journal of Hematology & Oncology

Prognostic Values of CCNE1 Amplification and Overexpression in Cancer Patients: A Systematic Review and Meta-analysis

(2018) Haiyue Zhao et al.   Journal of Cancer

19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes

(2018) Diar Aziz et al.   GYNECOLOGIC ONCOLOGY

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition

(2016) George Au-Yeung et al.   CLINICAL CANCER RESEARCH

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma

(2016) Elisabetta Kuhn et al.   MODERN PATHOLOGY

Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer

(2016) Aurelia Noske et al.   Oncotarget

CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas

(2015) KENTARO NAKAYAMA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Whole–genome characterization of chemoresistant ovarian cancer

(2015) Ann-Marie Patch et al.   NATURE

Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer

(2014) M. Alsina et al.   ANNALS OF ONCOLOGY

Synthetic lethality between CCNE1 amplification and loss of BRCA1

(2013) D. Etemadmoghadam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An integrated view of cyclin E function and regulation

(2012) Ka Tat Siu et al.   CELL CYCLE

Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses

(2012) Elisabetta Kuhn et al.   JNCI-Journal of the National Cancer Institute

Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer

(2010) C Caldon et al.   Cell Division

Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

(2009) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH